导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 9.83% | 734/4773 |
| 近一周 | -2.42% | 2116/5462 |
| 近一月 | -4.80% | 2764/5421 |
| 近一季 | -9.07% | 3089/5209 |
| 近半年 | -0.24% | 1252/4920 |
| 近一年 | 16.53% | 599/4366 |
| 近两年 | 89.09% | 696/2954 |
| 近三年 | 47.83% | 575/2253 |
| 成立以来 | 154.58% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.28% 550/4961 |
24.72% 1056/5312 |
- - |
- - |
| 2025 | 38.22% 874/4813 |
3.91% 1021/3635 |
4.34% 786/4076 |
22.90% 1600/4524 |
3.73% 639/4813 |
| 2024 | 3.54% 1920/3463 |
-2.73% 1418/2808 |
-4.12% 1468/3014 |
11.88% 2449/3129 |
-0.77% 1515/3463 |
| 2023 | -6.54% 854/2656 |
8.02% 503/2280 |
-3.83% 919/2385 |
-5.38% 1313/2515 |
-4.92% 1209/2655 |
| 2022 | -10.94% 223/2207 |
-11.76% 542/1919 |
3.21% 1192/2016 |
-4.26% 48/2113 |
2.15% 1028/2208 |
| 2021 | 22.34% 148/1822 |
0.96% 268/1255 |
11.04% 405/1330 |
7.34% 189/1466 |
1.66% 842/1822 |
| 2020 | 33.08% 465/1250 |
-3.11% 290/1028 |
18.79% 325/1067 |
12.89% 356/1164 |
2.42% 987/1184 |
| 2019 | - - |
- - |
- - |
6.38% 128/850 |
10.44% 133/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 万家中证500指数增强C VS. 长安沪深300非周期A(740101) |